Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Germán L. Farfalli"'
Autor:
Pablo, Dardanelli, José I, Albergo, Germán L, Farfalli, Pablo D, Roitman, Miguel A, Ayerza, Luis A, Aponte-Tinao
Publikováno v:
Medicina. 82(3)
Chondrosarcoma is the second most frequent primary malignant bone tumor. It is typically described in adults between 40 and 70 years of age, being the majority of the series published in this age group. The objective of this study was to report a ser
Autor:
Javier E. Sanchez-Saba, Mariano O. Abrego, José I. Albergo, Germán L. Farfalli, Luis A. Aponte-Tinao, Miguel A. Ayerza, Federico Cayol, Patricia Streitenberger, Marcelo R. Risk, Pablo D. Roitman
Publikováno v:
Medicina (Buenos Aires), Vol 80, Iss 1, Pp 23-30 (2020)
Ewing sarcoma of the bone is a rare, highly aggressive tumor that typically affects children and young adults. In Argentina, the lack of Ewing's sarcoma registries reflects in the absence of information regarding prevalence, treatment protocols and p
Autor:
Marcos R, Latorre, José I, Albergo, Germán L, Farfalli, Pablo D, Roitman, Luisa, Plantalech, Miguel A, Ayerza, Luis A, Aponte-Tinao
Publikováno v:
Medicina. 81(5)
Giant cell tumor of bone is an intermediate, locally aggressive and rarely metastasizing, primary bone neoplasia. In recent years denosumab emerged as a treatment alternative for this pathology. The objective of this work was to analyze its indicatio
Autor:
Germán L Farfalli, José I Albergo, Pablo A Lobos, David E Smith, Patricia D Streitenberger, María G Pallotta Rodríguez, Luis A Aponte-Tinao
Publikováno v:
Medicina (Buenos Aires), Vol 75, Iss 2, Pp 87-90 (2015)
La supervivencia global a 5 años de los pacientes con osteosarcoma no-metastásico es del 60-70%, mientras que la misma se reduce a 10-30% en los pacientes con enfermedad diseminada. El objetivo de nuestro estudio fue determinar supervivencia y fact
Publikováno v:
Revista de la Asociación Argentina de Ortopedia y Traumatologia, Vol 77, Iss 3, Pp 192-196 (2012)
Background The purpose of this study was to evaluate the survival, the complications and the functional outcome of intercalary tibial allografts reconstructions following tumor resections. Methods Intercalary tibia segmental allografts were implanted
Autor:
José I, Albergo, Germán L, Farfalli, Miguel A, Ayerza, Domingo L, Muscolo, Luis A, Aponte-Tinao
Publikováno v:
Medicina. 75(5)
The objective of the study was to analyze a group of patients with low grade parosteal osteosarcoma treated with limb salvage surgery and reconstructed with bone allograft. A retrospective review from our oncologic data base between 1980 and 2010 was
Autor:
Germán L, Farfalli, José I, Albergo, Pablo A, Lobos, David E, Smith, Patricia D, Streitenberger, María G, Pallotta Rodríguez, Luis A, Aponte-Tinao
Publikováno v:
Medicina. 75(2)
Five years overall survival in osteosarcoma patients is around 70%, although in patients with metastatic disease it is only 10-30%. The objective of this study was to analyze overall survival and prognostic factors in a group of patients with metasta
Autor:
Virginia M Cafruni, Angeles Cabas Geat, Jose F Labella, German L. Farfalli, Miguel A. Ayerza, Luis A Aponte-Tinao, Jose I Albergo
Publikováno v:
Revista de la Facultad de Ciencias Médicas de Córdoba, Vol 79, Iss 1 (2022)
Introducción El objetivo del estudio fue analizar las residencias ortopedia y traumatología en Argentina y determinar: 1) La proporción de mujeres; 2) Diferencias sociales y demográficas entre géneros: 3) Los factores que influyen positiva o
Externí odkaz:
https://doaj.org/article/819c9d488a0f438b9dc12f95ac13b081
Autor:
German L. Farfalli, Luis A. Aponte-Tinao, Miguel A. Ayerza, D. Luis Muscolo, Patrick J. Boland, Carol D. Morris, Edward A. Athanasian, John H. Healey
Publikováno v:
Sarcoma, Vol 2013 (2013)
Allograft-prosthesis composite (APC) can restore capsular and ligamentous tissues of the knee sacrificed in a tumor extirpation. We asked if performing APC would restore knee stability and allow the use of nonconstrained arthroplasty while preventing
Externí odkaz:
https://doaj.org/article/a44be2b8ecd1447ebd2b8a7a8037a191